TY - JOUR T1 - IL-6 and D-Dimer at Admission Predicts Cardiac Injury and Early Mortality during SARS-CoV-2 Infection JF - medRxiv DO - 10.1101/2021.03.22.21254077 SP - 2021.03.22.21254077 AU - Daoyuan Si AU - Beibei Du AU - Bo Yang AU - Lina Jin AU - Lujia Ni AU - Qian Zhang AU - Zhongfan Zhang AU - Mohammed Ali Azam AU - Patrick F.H. Lai AU - Stéphane Massé AU - Huan Sun AU - Xingtong Wang AU - Slava Epelman AU - Patrick R. Lawler AU - Ping Yang AU - Kumaraswamy Nanthakumar Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/29/2021.03.22.21254077.abstract N2 - BACKGROUND We recently described mortality of cardiac injury in COVID-19 patients. Admission activation of immune, thrombotic biomarkers and their ability to predict cardiacinjury and mortality patterns in COVID-19 is unknown.METHODS This retrospective cohort study included 170 COVID-19 patients with cardiac injury at admission to Tongji Hospital in Wuhan from January 29–March 8, 2020. Temporal evolution of inflammatory cytokines, coagulation markers, clinical, treatment and mortality were analyzed.RESULTS Of 170 patients, 60 (35.3%) died early (<21d) and 61 (35.9%) died after prolonged stay. Admission lab work that correlated with early death were elevate levels of interleukin 6 (IL-6) (p<0.0001), Tumor Necrosis Factor-a (TNF-a) (p=0.0025), and C-reactive protein (CRP) (p<0.0001). We observed the trajectory of biomarker changes after admission, and determined that early mortality had a rapidly increasing D-dimer, gradually decreasing platelet and lymphocyte counts. Multivariate and simple linear regression models showed that death risk was determined by immune and thrombotic pathway activation. Increasing cTnI levels were associated with those of increasing IL-6 (p=0.03) and D-dimer (p=0.0021). Exploratory analyses suggested that patients that received heparin has lower early mortality compared to those who did not (p =0.07), despite similar risk profile.CONCLUSIONS In COVID-19 patients with cardiac injury, admission IL-6 and D-dimer predicted subsequent elevation of cTnI and early death, highlighting the need for early inflammatory cytokine-based risk stratification in patients with cardiac injury.Condensed Abstract COVID-19 with cardiac injury is associated with worse survival. Admission activation of immune, thrombotic biomarkers and their ability to predict cardiac injury and mortality patterns in COVID-19 is unknown. This study proved that cardiac injury in these patients is closely related to the activation of immunological and thrombotic pathways and can be predicted by admission biomarkers of these pathways. This study supports the strategy of biomarker-guided, point-of-care therapy that warrants further studies in a randomized manner to develop anti-immune and anti-thrombotic treatment regimens in severe COVID-19 patients with cardiac injury.Competing Interest StatementK.N. is a consultant for Abbott, Biosense Webster, BlueRock and Servier. P. R. Lawler receives consulting fees from Brigham and Women's Hospital (Boston, MA) and Corrona LLC (Waltham, MA), and royalties from McGraw-Hill Publishing (New York, NY). The remaining authors have nothing to disclose.Clinical TrialChinese Clinical Trial Registry. (ChiCTR2000031301)Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This retrospective study (ChiCTR2000031301) was approved by the Institutional Ethics Board of the Third Hospital of Jilin University (approval number 2020032619), Tongji Hospital of Huazhong University of Science and Technology (approval number TJ-IRB20200345) and the University Health Network (REB#20-5322).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. ER -